ArticleTranslational andrology and urology2012
Future perspectives of prostate cancer therapy.
Article in Translational andrology and urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.Cellular and molecular life sciences : CMLS · 2020Review
- Roles of Reactive Oxygen Species in Biological Behaviors of Prostate Cancer.BioMed research international · 2020Review
- Prostate cancer cells specifically reorganize epithelial cell-fibroblast communication through proteoglycan and junction pathways.Cell adhesion & migration · 2017Article
- SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.Oncotarget · 2015Article
- Increased expression of ACTH (MC2R) and androgen (AR) receptors in giant bilateral myelolipomas from patients with congenital adrenal hyperplasia.BMC endocrine disorders · 2014Article
- Optimization of apparent diffusion coefficient measured by diffusion-weighted MRI for diagnosis of breast lesions presenting as mass and non-mass-like enhancement.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Magnetic resonance imaging for prostate cancer clinical application.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2013Article
- WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone.PloS one · 2013Article
- Proteoglycan expression in normal human prostate tissue and prostate cancer.ISRN oncology · 2013Article
- Anacardic acid (6-pentadecylsalicylic acid) induces apoptosis of prostate cancer cells through inhibition of androgen receptor and activation of p53 signaling.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2012Article
- Stromal modulation of bladder cancer-initiating cells in a subcutaneous tumor model.American journal of cancer research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We summarize several recent laboratory advances to tackle the problem of tumor-stroma-immune cell microenvironment interaction with the hope of developing and advancing new concepts and therapeutic strategies for prostate cancer therapy by improving bone and soft tissue metastases in prostate cancer patients. Given the emerging enthusiasm for immunotherapy in prostate cancer due to (I) improved understanding of the role of immune cells in the tumor microenvironment, (II) approval by the FDA of an immunotherapeutic drug to treat prostate cancer, and (III) recognition of immunotherapy as a novel approach to treat solid tumors by the Nobel Prize Committee (for discovery of dendritic cells that are used in immunotherapy), the field of tumor immunology is poised for growth in the next decade with the hope of developing new immunomodulatory drugs which will compliment and perhaps eventually replace traditional chemotherapeutic drugs. In this article, we provide a timely review of recent advances in the field of immunotherapy for prostate cancer, lessons learned from successes and failures, the contributory factors in the tumor microenvironment that could be rendered hostile to cancer cells, an exciting area of future research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.